Skip to main content
SpringerLink
Log in

Carcinoid Liver Metastases: The Carcinoid Syndrome

  • Chapter
  • First Online:
Liver Metastases

  • 912 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999; 340: 858–67.

    Article  PubMed  CAS  Google Scholar 

  2. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997; 79: 813–29.

    Article  PubMed  CAS  Google Scholar 

  3. Williams ED, Sandler M. The classification of carcinoid tumours. Lancet. 1963; 1: 238–9.

    Article  PubMed  CAS  Google Scholar 

  4. Bell HK, Poston GJ, Vora J, Wilson NJE. Cutaneous manifestations of the malignant carcinoid syndrome. Br J Dermatol. 2005; 152: 71–5.

    Article  PubMed  CAS  Google Scholar 

  5. Modlin IM, Shapiro MD, Kidd M. Carcinoid tumors and fibrosis: an association with no explanation. Am J Gastroenterol. 2004; 99: 2466–78.

    Google Scholar 

  6. Moller JE, Pellikka PA, Bernheim AM, et al. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation. 2005; 112: 3320–7.

    Google Scholar 

  7. Connolly HM, Pellikka PA. Carcinoid heart disease. Curr Cardiol Rep. 2006; 8: 96–101.

    Article  PubMed  Google Scholar 

  8. Robiolio PA, Rigolin VH, Harrison JK, et al. Predictors of outcome of tricuspid valve replacement in carcinoid heart disease. Am J Cardiol. 1995; 75: 485–8.

    Article  PubMed  CAS  Google Scholar 

  9. Connolly HM, Nishimura RA, Smith HC, et al. Outcomes of cardiac surgery for carcinoid disease. J Am Coll Cardiol. 1995; 25: 410–6.

    Article  PubMed  CAS  Google Scholar 

  10. Kobayashi K, Katsumata T, Yoshizawa S, et al. Indications for endoscopic polypectomy for rectal carcinoids and clinical usefulness of endoscopic ultrasonography. Dis Colon Rectum. 2005; 48: 285–91.

    Article  PubMed  Google Scholar 

  11. Anderson MA, Carpenter S, Thompson NW, et al. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000; 96: 2271–7.

    Google Scholar 

  12. Kaltsas G, Rockall A, Papdogias D, et al. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur J Endocrinol. 2004; 151: 15–27.

    Article  PubMed  CAS  Google Scholar 

  13. Janson ET, Westlin JE, Eriksson B, et al. [111In-DTPA-D-Phe1] octreotide scintigraphy in patients with carcinoid tumours: the predictive value for somatostatin analogue treatment. Eur J Endocrinol. 1994; 131: 577–81.

    Article  PubMed  CAS  Google Scholar 

  14. Savelli G, Lucignani G, Seregni E, et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun. 2004; 25: 445–9.

    Article  PubMed  Google Scholar 

  15. Bousquet C, Guillermet J, Vernejoul F, et al. Somatostatin receptors and regulation of cell proliferation. Dig Liver Dis. 2004; 36(S1): S2–7.

    Article  PubMed  CAS  Google Scholar 

  16. Kulaksiz H, Eissele R, Rossler D, et al. Identification of somatostatin receptor subtypes 1, 2A, 3 and 5 in neuroendocrine tumours with specific antibodies. Gut. 2002; 50: 52–60.

    Article  PubMed  CAS  Google Scholar 

  17. Hashemi SH, Benjegard SA, Ahlman H, et al. 111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours. Br J Surg. 2003; 90: 549–54.

    Article  PubMed  CAS  Google Scholar 

  18. Decristoforo C, Mather SJ, Cholewinski W, et al. 99mTc-EDDA/HYNAC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives. Eur J Nucl Med. 2000; 27: 1318–25,

    Google Scholar 

  19. Gabriel M, Decristoforo C, Maina T, et al. 99mTc-N4-[Tyr3]octreotate versus 99mTc-EDDA/HYNIC-[Tyr3]octreotide: an interpatient comparison of two novel technetium-99m labelled tracers for somatostatin receptor scintigraphy. Cancer Biother Radiopharm. 2004; 19: 73–9.

    Article  PubMed  CAS  Google Scholar 

  20. Forster GJ, Engelbach MJ, Brockmann JJ, et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur J Nucl Med. 2001; 28: 1743–50.

    Google Scholar 

  21. Otte A, Mueller-Brand J, Dellas S, et al. Yttrium-90-labelled somatostatin analogue for cancer treatment. Lancet. 1998; 351: 417–8.

    Article  PubMed  CAS  Google Scholar 

  22. Hoefnagel CA, Lewington VJ. MIBG therapy. In: Murray IPC, Ell PJ, eds. Nuclear Medicine, V01.2. Edinburgh: Churchill Livingstone; 1994: 851–64.

    Google Scholar 

  23. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001; 86: 895–902.

    Article  PubMed  CAS  Google Scholar 

  24. Sundin A, Eriksson B, bergstrom M, et al. PET in the diagnosis of neuroendocrine tumors. Ann NY Acad Sci. 2004; 1014: 246–57.

    Google Scholar 

  25. Orlefors H, Sundin A, Garske U, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab. 2005; 90: 3392–400.

    Google Scholar 

  26. Anderson CJ, Dehdashti F, Cutler PD, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001; 42: 213–21.

    PubMed  CAS  Google Scholar 

  27. Koopmans KP, de Vries EG, Kema IP, et al. Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol 2006; 7: 728–34.

    Article  PubMed  CAS  Google Scholar 

  28. Virgolini I, Patri P, Novotny C, et al. Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol. 2001; 12(2): S41–5.

    Article  PubMed  Google Scholar 

  29. Kowalski J, Henze M, Schuhmacher J, et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003; 5: 42–8.

    Article  PubMed  Google Scholar 

  30. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000; 190: 432–45.

    Article  PubMed  CAS  Google Scholar 

  31. Sutcliffe R, Maguire D, Ramage J, et al. Management of neuroendocrine liver metastases. Am J Surg. 2004; 187: 39–46.

    Article  PubMed  Google Scholar 

  32. Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am. 2003; 12: 321–42.

    Article  Google Scholar 

  33. Kinney MA, Warner ME, Nagorney DM, et al. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours. Br J Anaesth. 2001; 87: 447–52.

    Article  PubMed  CAS  Google Scholar 

  34. Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005; 241: 776–83.

    Article  PubMed  Google Scholar 

  35. Norton JA, Warren RS, Kelly MG, et al. Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery. 2003; 134: 1057–63.

    Google Scholar 

  36. Sarmiento JM, Heywood G, Rubin J, et al. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003; 197: 29–37.

    Article  PubMed  Google Scholar 

  37. Knox CD, Feurer ID, Wise PE, et al. Survival and functional quality of life after resection for hepatic carcinoid metastases. J Gastrointest Surg. 2004; 8: 653–9.

    Article  PubMed  Google Scholar 

  38. Chung MH, Pisegna J, Spirt M, et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery. 2001; 130: 954–62.

    Article  PubMed  CAS  Google Scholar 

  39. Gulec SA, Mountcastle TS, Frey D, et al. Cytoreductive surgery in patients with advanced-stage carcinoid tumors. Am Surg. 2002; 68: 667–71.

    PubMed  Google Scholar 

  40. Dick EA, Joarder R, de Jode M, et al. MR-guided laser thermal ablation of primary and secondary liver tumours. Clin Radiol. 2003; 58: 112–20.

    Article  PubMed  CAS  Google Scholar 

  41. Gillams A, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases—the Middlesex experience. Abdom Imaging. 2005; 30: 435–41.

    Article  PubMed  CAS  Google Scholar 

  42. Atwell TD, Charboneau JW, Que FG, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol. 2005; 28: 409–21.

    Article  PubMed  CAS  Google Scholar 

  43. Elias D, Sideris L, Liberale G, et al. Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery. 2005; 137: 411–6.

    Article  PubMed  Google Scholar 

  44. Jensen EH, Kvols L, McLaughlin JM, et al. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol. 2007; 14: 780–5.

    Article  PubMed  Google Scholar 

  45. Hirai I, Kimura W, Fuse A, et al. Surgical management for metastatic liver tumors. Hepatogastroenterology. 2006; 53: 757–63.

    PubMed  Google Scholar 

  46. Musunuru S, Chen H, Rajpal S, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006; 141: 1000–4.

    Google Scholar 

  47. Veenendaal LM, Rinkes IH, Lips CJ, van Hillegersberg R. Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy. World J Surg Oncol. 2006; 4: 35.

    Article  PubMed  Google Scholar 

  48. Osborne DA, Zervos EE, Strosberg J, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006; 13: 572–81.

    Article  PubMed  Google Scholar 

  49. Hodul P, Malafa M, Choi J, Kvols L. The role of cytoreductive surgery as an adjunct to the management of metastatic neuroendocrine carcinomas. Cancer Control. 2006; 13: 61–71.

    PubMed  Google Scholar 

  50. Givi B, Pommier SJ, Thompson AK, et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. 2006; 140: 891–8.

    Article  PubMed  Google Scholar 

  51. Ahlman H, Friman S, Cahlin C, et al. Liver transplantation for treatment of metastatic neuroendocrine tumors. Ann NY Acad Sci. 2004; 1014: 265–9.

    Google Scholar 

  52. Florman S, Toure B, Kim L, et al. Liver transplantation for neuroendocrine tumors. J Gastrointest Surg. 2004; 8: 208–12.

    Article  PubMed  Google Scholar 

  53. Frilling A, Malago M, Weber F, et al. Liver transplantation for patients with metastatic endocrine tumors: single-center experience with 15 patients. Liver Transpl. 2006; 12: 1089–96.

    Google Scholar 

  54. van Vilsteren FG, Baskin-Bey ES, Nagorney DM, et al. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. Liver Transpl. 2006; 12: 448–56.

    Article  PubMed  Google Scholar 

  55. Knox CD, Anderson CD, Lamps LW, et al. Long-term survival after resection for primary hepatic carcinoid tumor. Ann Surg Oncol. 2003; 10: 1171–5.

    Google Scholar 

  56. Fenwick SW, Wyatt JI, Toogood GJ, Lodge JP. Hepatic resection and transplantation for primary carcinoid tumors of the liver. Ann Surg. 2004; 239: 210–9.

    Article  PubMed  Google Scholar 

  57. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005; 104: 1590–602.

    Google Scholar 

  58. Meij V, Zuetenhorst JM, van Hillegersberg R, et al. Local treatment in unresectable hepatic metastases of carcinoid tumors: Experiences with hepatic artery embolization and radiofrequency ablation. World J Surg Oncol. 2005; 3: 75.

    Article  PubMed  Google Scholar 

  59. Strosberg JR, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006; 13: 72–8.

    PubMed  Google Scholar 

  60. Yao KA, Talamonti MS, Nemcek A, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001; 130: 677–82.

    Article  PubMed  CAS  Google Scholar 

  61. Dominguez S, Denys A, Madeira I, et al. Hepatic arterial chemoembolization with streptozotocin in patients with metastatic digestive endocrine tumours. Eur J Gastroenterol Hepatol. 2000; 12: 151–7.

    Article  PubMed  CAS  Google Scholar 

  62. Roche A, Girish BV, de Baere T, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol. 2003; 13: 136–40.

    PubMed  Google Scholar 

  63. Fiorentini G, Rossi S, Bonechi F, et al. Intra-arterial chemoembolization in liver metastases from neuroendocrine tumors: a phase II study. J Chemother. 2004; 16: 293–7.

    PubMed  CAS  Google Scholar 

  64. Dong XD, Yin X, Zeh HJ, et al. Long-term outcome in patients with liver metastases from neuroendocrine tumors treated with chemoembolization. Proc ASCO. 2005; 23: 349S (abstract 4167).

    Google Scholar 

  65. Gupta S, Johnson MM, Murthy R, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors. Cancer. 2005; 104(8): 1590–602.

    Article  PubMed  Google Scholar 

  66. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastrointestinal system. Ann Oncol. 2004; 15: 966–73.

    Google Scholar 

  67. Rubin J, Ajani J, Schirmer W, et al. Octretide acetate long-acting formulation versus open-labelled subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999; 17: 600–6.

    PubMed  CAS  Google Scholar 

  68. Filosso PL, Ruffini E, Oliaro A, et al. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg. 2002; 21: 913–7.

    Article  PubMed  Google Scholar 

  69. Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol. 2004; 151: 107–12.

    Article  PubMed  CAS  Google Scholar 

  70. Woltering E, Mamikunian PM, Zeitz S, et al. Octreotide acetate (LAR) dose effect on plasma octreotide levels: impact on neuroendocrine tumor management. Proc ASCO. 2005; 23: 235S (abstract 3177).

    Google Scholar 

  71. Fykse V, Sandvik AK, Qvigstad G, et al. Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol. 2004; 39: 621–8.

    Article  PubMed  CAS  Google Scholar 

  72. Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000; 95: 3276–81.

    Google Scholar 

  73. Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol. 2000; 23: 412–5.

    Article  PubMed  CAS  Google Scholar 

  74. O’Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000; 88: 770–6.

    Article  PubMed  Google Scholar 

  75. Hoefnagel CA, Taal BG, Sivro F, et al. Enhancement of 131I-MIBG uptake in carcinoid tumours by administration of unlabelled MIBG. Nucl Med Commun. 2000; 21: 755–61.

    Article  PubMed  CAS  Google Scholar 

  76. Mukherjee JJ, Kaltsas GA, Islam N, et al. Treatment of metastatic carcinoid tumours, phaeochromocytomas, paraganglionoma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol. 2001; 55: 47–60.

    Article  CAS  Google Scholar 

  77. Kolby L, Bernhardt P, Levin-Jakobsen AM, et al. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer. 2003; 89: 1383–8.

    Google Scholar 

  78. Sywak MS, Pasieka JL, McEwan A, et al. 131I-meta-iodobenzylguanidine in the management of midgut carcinoid tumors. World J Surg. 2004; 28: 1157–62.

    Article  Google Scholar 

  79. Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer. 2004; 101: 1987–93.

    Google Scholar 

  80. Valkema R, Kvols LK, Pawels S, et al. Peptide receptor radiotherapy (PRRT) with [Y-90-DOTA, Tyr3]octreotide: toxicity and efficacy of 4-cycle and single-cycle regimens. Proc ASCO. 2004; 23: 206 (abstract 3046).

    Google Scholar 

  81. Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. Radiolabelled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005; 23: 2754–62.

    Google Scholar 

  82. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabelled somatostatin analogs. J Nucl Med. 2005; 46: 62S–66S.

    PubMed  CAS  Google Scholar 

  83. Davi MV, Bodei L, Francia G, et al. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). J Endocrinol Invest. 2006; 29: 563–7.

    PubMed  CAS  Google Scholar 

  84. Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interfer90n alpha on survival in patients with disseminated carcinoid tumours. Br J Surg. 2003; 90: 687–93.

    Article  PubMed  CAS  Google Scholar 

  85. Stuart K, Levy DE, Anderson T, et al. Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group. Invest New Drugs. 2004; 22: 75–81.

    Article  PubMed  CAS  Google Scholar 

  86. Wirth LJ, Carter MR, Janne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer. 2004; 44: 213–20.

    Article  PubMed  Google Scholar 

  87. Hopfner M, Sutter AP, Huether A, et al. A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine. BMC Cancer. 2004; 4: 23.

    Article  PubMed  Google Scholar 

  88. Zuetenhorst JM, Valdes Olmos RA, Muller M, et al. Interferon and meta-iodobenzylguanidin combinations in the treatment of metastatic carcinoid tumours. Endocr Relat Cancer. 2004; 11: 553–61.

    Article  PubMed  CAS  Google Scholar 

  89. Pape UF, Wiedenmann B. Adding interferon-alpha to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours. Cancer Treat Rev. 2003; 29: 565–9.

    Article  PubMed  Google Scholar 

  90. Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozotocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group study E1281. J Clin Oncol. 2005; 23: 4897–904.

    Google Scholar 

  91. Kulke MH, Kim H, Stuart K, et al. A phase II study of decetaxel in patients with metastatic carcinoid tumors. Cancer Invest. 2004; 22: 353–9.

    Article  PubMed  CAS  Google Scholar 

  92. Kegel T, Grothe A, Jordan M, et al. Paclitaxel, carboplatin and etoposid (TCE) in the treatment of advanced neuroendocrine tumours. Proc ASCO. 2005; 23: 373S (abstract 4263).

    Google Scholar 

  93. Miranda FT, Spigel DR, Hainsworth JD, et al. Paclitaxel/carboplatin/etoposide (PCE) therapy for advanced poorly differentiated neuroendocrine (PDNE) carcinoma: a Minnie Pearl Cancer Network phase II trial. Proc ASCO. 2005; 23: 322S (abstract 4058).

    Google Scholar 

  94. Hopfner M, Sutter AP, Berst B, et al. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer. 2003; 89: 1766–75.

    Google Scholar 

  95. Kulke M, Lenz HJ, Meropol NJ, et al. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients with unresectable neuroendocrine tumors. Proc ASCO. 2005; 23: 310S (abstract 4008).

    Google Scholar 

  96. Hobday TJ, Mahoney M, Erlichman C, et al. Preliminary results of a phase II trial of gefitinib in progressive metastatic neuroendocrine tumors (NET): a phase II Consortium (P2C) study. Proc ASCO. 2005; 23: 328S (abstract 4084).

    Google Scholar 

  97. Yao JC, Charnsangavej S, Faria SC, et al. Rapid decrease in blood flow, blood volume and vascular permeability in carcinoid patients treated with bevacizumab. Proc ASCO. 2004; 23: 198 (abstract 3013).

    Google Scholar 

  98. Yao JC, Ng C, Hoff PM, et al. Improved progression free survival, and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. Proc ASCO. 2005; 23: 309S (abstract 4007).

    Google Scholar 

  99. Mares JE, Worah S, Mathew SV, et al. Increased rate of hypertension among patients with advanced carcinoid treated with bevacizumab. Proc ASCO. 2005; 23: 329S (abstract 4087).

    Google Scholar 

  100. Carr K, Yao JC, Rashid A, et al. A phase II trial of imatinib in patients with advanced carcinoid tumor. Proc ASCO. 2005; 23: 343 (abstract 4124).

    Google Scholar 

  101. Shah MH, Young D, Kindler HL, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res. 2004; 10: 6111–8.

    Google Scholar 

  102. Duran I, Le L, Saltman D, et al. A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas. Pro ASCO. 2005; 23: 215S (abstract 3096).

    Google Scholar 

  103. Aaronson NK, Cull A, Kaasa S, Sprangers M. The EORTC modular approach to quality of life assessment in oncology. Int J Mental Health. 1994; 23: 75–96.

    Google Scholar 

  104. Shumaker SA, Naughton MJ. The international assessment of health-related quality of life: a theoretical perspective. In: Schumaker SA, Bernzon R, eds. The International Assessment of Health-Related Quality of Life: Theory, Translation, Measurement and Analysis. Oxford: Rapid Communications of Oxford; 1995: 3–10.

    Google Scholar 

  105. Larsson G, Haglund K, Von Essen L. Distress, quality of life and strategies to ‘keep a good mood’ in patients with carcinoid tumours: patient and staff perceptions. Eur J Cancer Care (Engl ). 2003; 12: 46–57.

    Article  CAS  Google Scholar 

  106. O’Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000; 88: 770–6.

    Article  PubMed  Google Scholar 

  107. Davies AH, Larsson G, Ardill J, et al. Development of a disease-specific Quality of Life questionnaire module for patients with gastrointestinal neuroendocrine tumours. Eur J Cancer. 2006; 42: 477–84.

    Article  PubMed  CAS  Google Scholar 

  108. Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality of life assessment in cancer clinical trials. Recent Results Cancer Res. 1988; 111: 231–49.

    Article  PubMed  CAS  Google Scholar 

  109. Sprangers MA, Cull A, Groenvold M, et al. The European Organisation for Research and Treatment of Cancer approach to developing questionnaire modules: an update and overview. EORTC Quality of Life Study Group. Qual Life Res. 1998; 7(4): 291–300.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgery, Digestive Diseases, Critical Care and Anaesthesia, Centre for Digestive Diseases, University Hospital Aintree, Liverpool, UK

    Graeme J. Poston

Authors
  1. John Bendelow
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Louise Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Graeme J. Poston
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. M.D. Anderson Cancer Center, Dept. Surgical Oncology, University of Texas, Holcombe Blvd. 1515, Houston, 77030, Texas, USA

    Jean-Nicolas Vauthey

  2. São Paulo, Faculdade de Medicina da, Universidade de São Paulo,, Instituto do Cancer do Estado de, Ave Dr Arnaldo 251, São Paulo, 01246-000, São Paulo, Brazil

    Paulo M. Hoff

  3. University of Liverpool, St Helens Teach, Marshalls Cross Road, St Helens, WA9 3DA, United Kingdom

    Riccardo A. Audisio

  4. Center for Digestive Diseases, University Hospital Aintree, Lower Lane, Liverpool, L9 7AL, United Kingdom

    Graeme J. Poston

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag London

About this chapter

Cite this chapter

Bendelow, J., Jones, L., Poston, G.J. (2009). Carcinoid Liver Metastases: The Carcinoid Syndrome. In: Vauthey, JN., Hoff, P., Audisio, R., Poston, G. (eds) Liver Metastases. Springer, London. https://doi.org/10.1007/978-1-84628-947-7_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-947-7_13

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-946-0

  • Online ISBN: 978-1-84628-947-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation